JP2024533123A5 - - Google Patents
Info
- Publication number
- JP2024533123A5 JP2024533123A5 JP2024513756A JP2024513756A JP2024533123A5 JP 2024533123 A5 JP2024533123 A5 JP 2024533123A5 JP 2024513756 A JP2024513756 A JP 2024513756A JP 2024513756 A JP2024513756 A JP 2024513756A JP 2024533123 A5 JP2024533123 A5 JP 2024533123A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- composition according
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240280P | 2021-09-02 | 2021-09-02 | |
| US63/240,280 | 2021-09-02 | ||
| US202263341318P | 2022-05-12 | 2022-05-12 | |
| US63/341,318 | 2022-05-12 | ||
| US202263390216P | 2022-07-18 | 2022-07-18 | |
| US63/390,216 | 2022-07-18 | ||
| PCT/US2022/075789 WO2023034881A1 (en) | 2021-09-02 | 2022-08-31 | Temperature-controllable, rna immunotherapeutic for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533123A JP2024533123A (ja) | 2024-09-12 |
| JP2024533123A5 true JP2024533123A5 (https=) | 2025-08-27 |
Family
ID=85413084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513756A Pending JP2024533123A (ja) | 2021-09-02 | 2022-08-31 | がんのための温度制御可能なｒｎａ免疫療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240350605A1 (https=) |
| EP (1) | EP4395817A4 (https=) |
| JP (1) | JP2024533123A (https=) |
| WO (1) | WO2023034881A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002509729A (ja) * | 1998-03-27 | 2002-04-02 | サイトス バイオテクノロジー アーゲー | 誘導性のアルファウイルス遺伝子発現系 |
| AU2008338803B2 (en) * | 2007-11-26 | 2015-02-05 | Glaxosmithkline Biologicals S.A. | Methods of generating alphavirus particles |
| WO2017152042A2 (en) * | 2016-03-04 | 2017-09-08 | New York University | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity |
| WO2018161092A1 (en) * | 2017-03-03 | 2018-09-07 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
| JP2021524247A (ja) * | 2018-05-23 | 2021-09-13 | グリットストーン バイオ インコーポレイテッド | 免疫チェックポイント阻害剤の共発現ベクター |
| KR20220128367A (ko) * | 2019-12-31 | 2022-09-20 | 엘릭서젠 쎄라퓨틱스, 인크. | Zscan4 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달 |
| MX2022007905A (es) * | 2019-12-31 | 2022-08-25 | Elixirgen Therapeutics Inc | Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos. |
-
2022
- 2022-08-31 WO PCT/US2022/075789 patent/WO2023034881A1/en not_active Ceased
- 2022-08-31 EP EP22865781.3A patent/EP4395817A4/en active Pending
- 2022-08-31 JP JP2024513756A patent/JP2024533123A/ja active Pending
- 2022-08-31 US US18/688,336 patent/US20240350605A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kallen et al. | A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs | |
| Ulmer et al. | RNA-based vaccines | |
| CN101827606B (zh) | Rna疫苗 | |
| Donnelly et al. | Antigen presentation and DNA vaccines | |
| Maruggi et al. | Self-amplifying mRNA-based vaccine technology and its mode of action | |
| JP2021525076A5 (https=) | ||
| ES2877160T3 (es) | Formulación para administración de ARN | |
| JP2016521539A5 (https=) | ||
| JP2021509107A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよびその使用 | |
| JP2023523414A5 (https=) | ||
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| JP2000508893A (ja) | プラスモウイルス由来の新規ワクチン | |
| TW202108598A (zh) | 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途 | |
| CN106459997A (zh) | 用于疫苗应用的高效价病毒样囊泡的进化 | |
| JP2023521662A5 (https=) | ||
| Zajakina et al. | Application of alphaviral vectors for immunomodulation in cancer therapy | |
| CN102083463B (zh) | 编码甲病毒属复制酶的表达载体及其作为免疫佐剂的用途 | |
| ES2585735T3 (es) | Nuevas proteínas de fusión y su aplicación para la preparación de vacunas contra la hepatitis C | |
| JP2016514672A (ja) | 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン | |
| JP2024533123A5 (https=) | ||
| JP2024542126A5 (https=) | ||
| Goold et al. | Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors | |
| JP2020526202A5 (https=) | ||
| CN110225976B (zh) | 用于激活sting途径的基因佐剂表达的病毒载体构建体 | |
| JP2023011701A (ja) | Ｃｄ４０およびｓｔｉｎｇ経路を活性化する遺伝子アジュバントの発現のためのウイルスベクター構築物 |